Viewing 1107 results
Dermatology
Assessing Subjective Burden in Patients with Atopic Dermatitis

Assessing Subjective Burden in Patients with Atopic Dermatitis
By :
Pro.Jonathan & Prof.Melinda
Dermatology
Assessing Clinical Severity in Patients with Atopic Dermatitis

Assessing Clinical Severity in Patients with Atopic Dermatitis
By :
Pro.Jonathan & Prof.Melinda
Dermatology
Assessing lack of treatment response in patients with Atopic Dermatitis

Assessing lack of treatment response in patients with Atopic Dermatitis
By :
Pro.Jonathan & Prof.Melinda
Dermatology
Targeting IL-13: Does It Scratch the Itch in Atopic Dermatitis?

Targeting IL-13: Does It Scratch the Itch in Atopic Dermatitis?
By :
Dr. Sarina Elmariah
Dermatology
The AD Saga Measuring Eligibility for Systemic Therapy

The AD Saga Measuring Eligibility for Systemic Therapy
By :
Pro.Jonathan & Prof.Melinda
Diabetes
Introducing Mounjaro: A Once-Weekly, First-in-Class GIP and GLP-1 Receptor Agonist

Introducing Mounjaro: A Once-Weekly, First-in-Class GIP and GLP-1 Receptor Agonist
By :
Lilly Saudi Arabia
Neurology
Barriers and benefits to a timely diagnosis

Barriers and benefits to a timely diagnosis
By :
Prof.Dr.Liz Coulthard
Neurology
Tracking the pathology of Alzheimer's disease

Tracking the pathology of Alzheimer's disease
By :
Prof.Sylvan Lehmann
Neurology
State-of-the-art biomarker toolkit

State-of-the-art biomarker toolkit
By :
Dr. Fortea and Prof. Shi
Neurology
Disclosing biomarker results+B2:B5

Disclosing biomarker results+B2:B5
By :
Prof. Dr. Kenjiro & Prof. Dr. Jens
Oncology
Jaypirca: A Novel BTK Inhibitor With a Well-Tolerated Safety Profile

Jaypirca: A Novel BTK Inhibitor With a Well-Tolerated Safety Profile

By :
Dr.Chaves
Oncology
How Does Jaypirca Work? The Science Explained

How Does Jaypirca Work? The Science Explained
By :
Dr Alan Skarbnik
Show More

Call Center          920008161

[email protected]

About Us
Support
Technical Requirements
VMA Team
Partner
© VMA 2025